{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:06:24Z","timestamp":1775106384193,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13555-026-01698-x","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T13:59:48Z","timestamp":1772200788000},"page":"2019-2030","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perspectives and Real-World Clinical Practice of Portuguese Dermatologists on Biologic Dose Spacing in Psoriasis: Results from a Nationwide Survey"],"prefix":"10.1007","volume":"16","author":[{"given":"C\u00e9sar","family":"Ferreira","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"issue":"19","key":"1698_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360. https:\/\/doi.org\/10.1001\/jama.2020.4006. (PMID: 32427307).","journal-title":"JAMA"},{"issue":"10281","key":"1698_CR2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301\u201315. https:\/\/doi.org\/10.1016\/S0140-6736(20)32549-6. (PMID: 33812489).","journal-title":"Lancet"},{"issue":"1","key":"1698_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-025-00630-5","volume":"11","author":"AW Armstrong","year":"2025","unstructured":"Armstrong AW, Blauvelt A, Callis Duffin K, Huang YH, Savage LJ, Guo L, et al. Psoriasis. Nat Rev Dis Primers. 2025;11(1):45. https:\/\/doi.org\/10.1038\/s41572-025-00630-5. (PMID: 40571687).","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1698_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s40262-023-01341-4","volume":"63","author":"J Greenzaid","year":"2024","unstructured":"Greenzaid J, Feldman S. Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of moderate-to-severe psoriasis. Clin Pharmacokinet. 2024;63(2):137\u201353. https:\/\/doi.org\/10.1007\/s40262-023-01341-4. (Epub 2024 Jan 27. PMID: 38280146).","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1698_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40265-020-01448-z","volume":"81","author":"CAJ Michielsens","year":"2021","unstructured":"Michielsens CAJ, van Muijen ME, Verhoef LM, van den Reek JMPA, de Jong EMGJ. Dose tapering of biologics in patients with psoriasis: a scoping review. Drugs. 2021;81(3):349\u201366. https:\/\/doi.org\/10.1007\/s40265-020-01448-z.","journal-title":"Drugs"},{"issue":"6","key":"1698_CR6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/ddg.15686","volume":"23","author":"L Mastorino","year":"2025","unstructured":"Mastorino L, Dapavo P, Ortoncelli M, Bongiovanni E, Quaglino P, Ribero S. IL-17 and IL-23 inhibitors dose spacing in adult psoriatic patients: a real-world pilot study. J Dtsch Dermatol Ges. 2025;23(6):693\u20139. https:\/\/doi.org\/10.1111\/ddg.15686. (Epub 2025 Apr 26. PMID: 40285562; PMCID: PMC12152515).","journal-title":"J Dtsch Dermatol Ges"},{"key":"1698_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01588-8","author":"M Luz","year":"2025","unstructured":"Luz M, Jo\u00e3o AL, Mendes-Bastos P, Roda \u00c2, Leite L, Val\u00e9rio J, et al. Real-World evidence on dose spacing of risankizumab for psoriasis: a multicenter retrospective cohort study. Dermatol Ther (Heidelb). 2025. https:\/\/doi.org\/10.1007\/s13555-025-01588-8. (Epub ahead of print. PMID: 41214414).","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"1698_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00403-021-02273-4","volume":"314","author":"ME van Muijen","year":"2022","unstructured":"van Muijen ME, van der Schoot LS, van den Reek JMPA, de Jong EMGJ. Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide. Arch Dermatol Res. 2022;314(7):687\u201395. https:\/\/doi.org\/10.1007\/s00403-021-02273-4. (Epub 2021 Aug 31. PMID: 34467442; PMCID: PMC9307528).","journal-title":"Arch Dermatol Res"},{"key":"1698_CR9","doi-asserted-by":"publisher","unstructured":"Eyerich K, Asadullah K, Pinter A, Weisenseel P, Reich K, Paul C, Sabat R, Wolk K, Eyerich S, Lauffer F, Angsana J, Taut FJH, Kohler K, Chen Y, Sendecki J, Leung MWL, Wegner S, Personke Y, Gomez M, Kr\u00fcger N, Tabori S, Sch\u00e4kel K. Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial. JAMA Dermatol. 2024;160(9):953\u201363. https:\/\/doi.org\/10.1001\/jamadermatol.2024.2463. (Erratum in: JAMA Dermatol. 2024 Nov 1;160(11):1257. 10.1001\/jamadermatol.2024.4370. PMID: 39083288; PMCID: PMC11292573).","DOI":"10.1001\/jamadermatol.2024.2463"},{"issue":"2","key":"1698_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/exd.70062","volume":"34","author":"L Mastorino","year":"2025","unstructured":"Mastorino L, Dapavo P, Ortoncelli M, Bongiovanni E, Liao Y, Leo F, et al. Dose modulation strategies in psoriatic patients: real-life pilot comparison between risankizumab and guselkumab up to 12\u00a0months after dose spacing. Exp Dermatol. 2025;34(2):e70062. https:\/\/doi.org\/10.1111\/exd.70062. (PMID: 39957279; PMCID: PMC11831094).","journal-title":"Exp Dermatol"},{"issue":"1","key":"1698_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/1744666X.2023.2250918","volume":"20","author":"L Rusi\u00f1ol","year":"2024","unstructured":"Rusi\u00f1ol L, Carmona-Rocha E, Puig L. Durability and long-term outcomes of biologic therapies in psoriasis. Expert Rev Clin Immunol. 2024;20(1):71\u201382. https:\/\/doi.org\/10.1080\/1744666X.2023.2250918. (Epub 2023 Aug 25. PMID: 37610817).","journal-title":"Expert Rev Clin Immunol"},{"issue":"11","key":"1698_CR12","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1093\/ced\/llaf250","volume":"50","author":"L Mastorino","year":"2025","unstructured":"Mastorino L, Dapavo P, Ortoncelli M, Bongiovanni E, Liao Y, Pelucchi M, et al. Dose modulation strategies in patients with psoriasis: real-world comparison between secukinumab and brodalumab for up to 1\u00a0year after dose spacing. Clin Exp Dermatol. 2025;50(11):2172\u20138. https:\/\/doi.org\/10.1093\/ced\/llaf250. (PMID: 40499920).","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"1698_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/exd.70122","volume":"34","author":"C Wang","year":"2025","unstructured":"Wang C, Liu Y, Yang Y, Ning J, Xing X, Jian P, et al. Extension of secukinumab and ixekizumab dose for moderate-to-severe psoriasis in low disease activity intervals. Exp Dermatol. 2025;34(5):e70122. https:\/\/doi.org\/10.1111\/exd.70122. (PMID: 40369849).","journal-title":"Exp Dermatol"},{"issue":"4","key":"1698_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/ijd.16915","volume":"63","author":"E Daud\u00e9n","year":"2024","unstructured":"Daud\u00e9n E, Escario E, Martos-Cabrera L, Armesto S, Herrera-Acosta E, Vidal D, et al. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting. Int J Dermatol. 2024;63(4):503\u201311. https:\/\/doi.org\/10.1111\/ijd.16915. (Epub 2024 Jan 2. PMID: 38168847).","journal-title":"Int J Dermatol"},{"issue":"1","key":"1698_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/1346-8138.16214","volume":"49","author":"MJ Gooderham","year":"2022","unstructured":"Gooderham MJ, Lynde C, Turchin I, Avadisian M, Labelle M, Papp KA. Real-world, long-term treatment patterns of commonly used biologics in Canadian patients with moderate-to-severe chronic plaque psoriasis. J Dermatol. 2022;49(1):95\u2013105. https:\/\/doi.org\/10.1111\/1346-8138.16214. (Epub 2021 Nov 7. PMID: 34747071; PMCID: PMC9298415).","journal-title":"J Dermatol"},{"issue":"4","key":"1698_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","volume":"22","author":"A Thatiparthi","year":"2021","unstructured":"Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol. 2021;22(4):425\u201342. https:\/\/doi.org\/10.1007\/s40257-021-00603-w. (Epub 2021 Apr 16. PMID: 33861409; PMCID: PMC8051287).","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1698_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13599","volume":"33","author":"L Shi","year":"2020","unstructured":"Shi L, Lian N, Liu L, Chen M. Tapering and discontinuation of systemic medications in psoriasis patients with low disease activity. Dermatol Ther. 2020;33(4):e13599. https:\/\/doi.org\/10.1111\/dth.13599. (Epub 2020 Jul 15. PMID: 32415804).","journal-title":"Dermatol Ther"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01698-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01698-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01698-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:38:44Z","timestamp":1775101124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01698-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1698"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01698-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C\u00e9sar Silva Ferreira has no conflicts of interest. Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Apogee, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Oruka, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, Sun Pharma, Takeda, and UCB. Tiago Torres is an Editorial Board member of Dermatology and Therapy. Tiago Torres was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"In Portugal, ethical approval by a Research Ethics Committee is legally required for studies that fall under the scope of clinical research, as defined by Law No. 21\/2014 of 16 April (Lei da Investiga\u00e7\u00e3o Cl\u00ednica). This law applies to interventional and non-interventional clinical studies conducted in human participants or involving individual health data. The present study consisted of an anonymous, voluntary, web-based survey of healthcare professionals and did not involve patients, clinical interventions, biological samples, or the collection of individual health data. As such, it does not meet the legal definition of a clinical study under Law No. 21\/2014 and therefore does not require prior approval. The study was conducted in accordance with general ethical principles and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}